
A phase 2 study of ABBV-154 in glucocorticoid-dependent polymyalgia rheumatica (PMR) showed that ABBV-154 significantly extended time to flare compared to placebo, with the 340 mg dose having the greatest effect (hazard ratio 0.20, p < 0.001). ABBV-154 was generally well tolerated, with no major differences in adverse events between groups. However, the study was terminated early, and the results should be interpreted cautiously.
Like
Save
Share